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Introduction
•   Venous thromboembolism (VTE) is the third most common cardiovascular 
disease, affecting about 10 million people globally each year1
•   Edoxaban, a non-vitamin K antagonist oral anticoagulant (NOAC), is 
approved for the treatment and secondary prevention of acute VTE in adults 
based on its comparable efficacy and superior safety to warfarin in a broad 
spectrum of patients with VTE during the Hokusai-VTE trial2  
•   During the treatment of VTE, obesity may affect the bioavailability, distribution 
and half-life of NOACs and, consequently, outcomes of treatment3
•   Dose reduction of edoxaban is recommended in patients with one or more of 
the following clinical factors: moderate or severe renal impairment (creatinine 
clearance 15–50 mL/min), body weight ≤60 kg, concomitant use of certain 
P-glycoprotein inhibitors4
•   ETNA-VTE-Europe (NCT02943993) was initiated in agreement with the 
European Medicines Agency (EMA) to assess benefits and risks of 
edoxaban treatment and secondary prevention of VTE with edoxaban up  
to 18 months in routine clinical practice5
Aim
•   Using data from the ETNA-VTE-Europe registry, our aim was to characterise 
obese patients and to investigate outcomes in patients treated with edoxaban 
categorised by BMI
Methods
•   ETNA-VTE-Europe is a single-arm, multinational, prospective, non-interventional 
post-authorisation safety study conducted in 310 sites in 8 European 
countries (NCT02943993)5
•   A total of 2,322 patients with acute VTE treated with edoxaban were 
enrolled, and will be followed-up for 18 months subsequent to the index VTE
•   The primary objective of ETNA-VTE-Europe was to assess the 18-month 
rate of symptomatic VTE recurrence in patients with VTE treated with 
edoxaban in clinical practice
•   The co-primary objective was to assess the real-world rates of bleeding and 
adverse drug reactions
•   This sub-study analysed outcomes in normal weight (BMI 18.5–25 kg/m2), 
overweight (BMI 25–30 kg/m2) and obese (BMI >30 kg/m2) patients enrolled 
into the ETNA-VTE-Europe study
•   Results for patients with BMI ≤18.5 kg/m2 are not reported due to low patient 
numbers in this subgroup (n=18) and 149 patient had missing BMI data
•   Patients with history of cancer, active cancer at baseline or new cancer 
within 6 months (182 days) after start of acute index VTE were excluded 
from the analysis to avoid confounding factors
Results
•   This snapshot analysis set included 2131 patients who completed 1-year 
follow-up
•   Of these patients, 573 were normal weight, 849 were overweight and 560 
were obese (Table 1)
•   Obese patients were more often female, had higher rates of hypertension, 
diabetes and prior VTE, chronic venous insufficiency and a higher eGFR 
than non-obese patients (Table 1)
•   Obese patients received the 60 mg edoxaban dose more often (Table 1)
•   At 1-year follow-up, overall VTE recurrence was 2.67% with consistent 
results across the range of BMI categories (Figure 1)
•   Any bleeding was observed in 12.29% and major bleeding in 1.69% with a 
numerical decrease in obese patients (Figure 2)
•   While all-cause mortality followed a U-shape association across BMI 
groups, there was a consistent trend for a reduced cardiovascular mortality 
in obese patients (Figure 3)
Table 1. Patient characteristics by BMI category
Patient characteristics Overall*
† 
(N=2131)
BMI  
18.5 to  
<25 kg/m2*
(N=573)
BMI  
25 to  
<30 kg/m2*
(N=849)
BMI  
≥30 kg/m2*
(N=560)
Female, n (%) 983 (46.1) 297 (51.8) 335 (39.5) 322 (51.3)
Age, years, mean ± SD 62.4 ± 16.07 61.9 ± 18.19 64.0 ± 14.93 61.9 ± 14.97
BMI, kg/m2, mean ± SD 27.9 ± 5.00 22.7 ± 1.85 27.3 ± 1.37 34.2 ± 4.04
recalc. eGFR (Cockroft-Gault),  
ml/min, mean ± SD 95.7 ± 38.95 82.1 ± 31.85 92.3 ± 34.60 114.0 ± 44.88
Frailty (physician judgement), n (%) 261 (12.2) 75 (13.1) 106 (12.5) 75 (11.9)
Medical history, n (%)
   Hypertension
   Diabetes mellitus
   Chronic venous insufficiency
   Bleeding history
   Ischaemic stroke
888 (41.7)
235 (11.0)
234 (11.0)
60 (2.8)
52 (2.4)
165 (28.8)
40 (7.0)
49 (8.6)
20 (3.5)
14 (2.4)
359 (42.3)
81 (9.5)
104 (12.2)
21 (2.5)
22 (2.6)
360 (57.3)
117 (18.6)
85 (13.5)
18 (2.9)
15 (2.4)
History of VTE, n (%)
   Prior PE±DVT
   Prior DVT
160 (7.5)
350 (16.4)
38 (6.6)
89 (15.5)
55 (6.5)
149 (17.6)
54 (8.6)
108 (17.2)
Edoxaban treatment at baseline, n (%)
   Edoxaban 60 mg
   Edoxaban 30 mg
1873 (87.9)
258 (12.1)
449 (78.4)
124 (21.6)
771 (90.8)
78 (9.2)
521 (93.0)
39 (7.0)
*Patients with history of cancer, active cancer at baseline or new cancer within 6 months (182 days) 
after start of acute index VTE were excluded from the analysis; †One hundred and forty-nine patients 
had missing BMI.
DVT, deep vein thrombosis; eGFR, estimated glomerular filtration rate; PE, pulmonary embolism;  
SD, standard deviation; VTE, venous thromboembolism
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Figure 1. Annualised efficacy event rates by BMI category 
*A total of 149 patients had missing BMI
†Patients with history of cancer, active cancer at baseline or new cancer within 6 months (182 days) after 
start of acute index VTE were excluded from analysis; DVT, deep vein thrombosis; GI, gastrointestinal; 
PE, pulmonary embolism; SE, systemic embolism; VTE, venous thromboembolism; SEE, systemic 
embolic events
Figure 2. Annualised safety event rates by BMI category 
*A total of 149 patients had missing BMI
†Patients with history of cancer, active cancer at baseline or new cancer within 6 months (182 days) 
after start of acute index VTE were excluded from analysis; CRNM, clinically relevant non-major;  
GI, gastrointestinal; ICH, intracranial haemorrhage; ISTH, International Society on Thrombosis  
and Haemostasis
Figure 3. Annualised mortality event rates by BMI category 
*A total of 149 patients had missing BMI
†Patients with history of cancer, active cancer at baseline or new cancer within 6 months (182 days) after 
start of acute index VTE were excluded from analysis; CV, cardiovascular
Conclusions
•   Obesity does not appear to substantially affect the risks 
of recurrent VTE and any bleeding complications in a 
contemporary cohort of edoxaban-treated patients
•   Apart from all-cause mortality following a U-shape 
association and CV mortality being numerically lowest 
in BMI ≥30, which may be due to chance, there were no 
appreciable differences in outcomes across the various 
subgroups
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